Domestic Policy Caucus

09/09/2026

DPC in RealClearHealth: CMS Is Reining in 340B Program Abuse – Rural Patients Will Benefit

Read about it here: https://www.domesticpolicycaucus.com/dpc-blog/dpc-in-realclearhealth-cms-is-reining-in-340b-program-abuse-rural-patients-will-benefit

08/31/2026

DPC Responds to CMS Request of Comments on Medicare Program, 340B Drug Pricing

Read about it here:

The Domestic Policy Caucus today responded to a Request for Comments on A Proposed Rule by the Centers for Medicare & Medicaid Services, “Medicare Program: Hospital Outpatient Prospective Payment and Ambulatory Surgical Center Payment Systems; and Quality Reporting Programs

08/10/2026

Coalition including DPC Urges Federal Regulators to Judge Bank License Applications on Qualifications, not Politics

Read about it here:

The Domestic Policy Caucus has signed onto a coalition letter urging federal regulators to judge bank license applications solely on qualifications, not on ideological agendas…

08/03/2026

DPC Applauds Call to Improve Bank Merger Review Process

Read about it here:

The Domestic Policy Caucus applauds members of the House Financial Services Committee who are urging the Federal Reserve to continue improving the efficiency of its bank merger review process…

07/30/2026

Former HHS Secretary Dr. Tom Price and Former U.S. Representative Dr. Larry Bucshon in the The Washington Times: CJR-X would hold a hospital responsible for 90 days of care it cannot direct, including treatment by clinicians and facilities it does not control. Read more about the absurdity of this program:

As physicians and conservatives, we have spent our careers working toward the same goal: improving patient care while being responsible stewards of taxpayer dollars.

07/27/2026

Yes!

California Can Show America How to Strengthen U.S. Drug Innovation.

California policymakers should demand accountability and transparency around the 340B program in our state.



https://californiaglobe.com/fr/california-can-show-america-how-to-strengthen-u-s-drug-innovation/

07/20/2026

S. 2355, up for markup Wednesday in the U.S. Senate HELP (Health, Education, Labor, and Pensions) Committee, creates redundant mandates for healthcare providers that ultimately harm patients without addressing the middlemen that are driving up out of pocket costs. A better approach is needed to improve access to care.

Executive Session on July 22, 2026 at 6:00 AM

07/10/2026

A one-size-fits-all mandate from Washington can't account for what an individual patient needs to recover. That judgment belongs to doctors and patients, not a federal payment formula.

HHS Secretary Tom Price, MD, & U.S. Rep. Larry Bucshon, MD, make the free-market case against CJR-X:

As physicians and conservatives, we have spent our careers working toward the same goal: improving patient care while being responsible stewards of taxpayer dollars.

06/25/2026

Insurer red tape like prior authorization puts care out of reach for too many Americans, delaying treatment insurers often approve anyway. We're glad to see Congress looking at healthcare costs & hope the focus lands where it belongs.

Read more:

In light of hearings on the cost of healthcare being held by the U.S. House Energy & Commerce Health Subcommittee today, the Domestic Policy Caucus is calling on Congress to focus on red tape and bureaucracy that hinders patients from getting the healthcare they need…

06/10/2026

All consumers, no matter their income level, deserve the freedom to borrow. Learn more at www.freedomtoborrow.org